FDA greenlights Stealth Bio’s injection as 1st treatment for Barth syndrome

Stealth BioTherapeutics has secured accelerated FDA approval for Forzinity (elamipretide), marking the first approved treatment for Barth syndrome, an ultrarare and life-limiting genetic disorder, for patients weighing at least 60 pounds. This approval, based on improved knee muscle strength and contingent on a post-marketing confirmatory trial, follows a tumultuous regulatory journey including prior rejections, significant delays, and public and congressional pressure, highlighting the challenges and financial pressures in developing therapies for rare diseases.

Analysis

Stealth BioTherapeutics has secured a critical accelerated FDA approval for Forzinity (elamipretide), the first-ever treatment for the ultrarare Barth syndrome. This regulatory green light, granted well ahead of the anticipated February 2026 PDUFA date, serves as a financial lifeline for the company, which was described as being on the 'brink of financial collapse' and had recently laid off 30% of its staff following a prior rejection in May. The approval's basis is a surrogate endpoint—improved knee muscle strength—rather than the previously failed primary endpoint of a six-minute walk test. Consequently, the FDA has mandated a post-approval, placebo-controlled confirmatory trial, creating a significant future binary risk event for the company. The decision followed intense public and political pressure, including letters from members of Congress and a coalition of scientists, which appears to have influenced the FDA's timeline and willingness to approve the therapy based on the intermediate clinical endpoint evidence.

Key Decisions for Investors

• The accelerated approval represents a significant positive catalyst and a fundamental turning point for Stealth BioTherapeutics, shifting its status from a distressed clinical-stage entity to a commercial one with a monopoly in an ultrarare disease.
• Investors must closely monitor the mandatory post-approval confirmatory trial, as its failure would likely result in the withdrawal of Forzinity from the market and erase the company's primary value driver.
• Attention should now pivot to the company's commercialization strategy, pricing, and initial sales trajectory for Forzinity, as successful execution is paramount to rebuilding its financial health and validating the investment thesis.